Why the study?
Patients with good-grade aneurysmal subarachnoid hemorrhage may experience secondary deterioration due to delayed cerebral ischemia, making neurological assessment challenging, and invasive neuromonitoring may help guide treatment.
Does invasive neuromonitoring improve functional outcomes at 12 months in good-grade subarachnoid hemorrhage patients with secondary deterioration?
Does invasive neuromonitoring improve functional outcomes at 12 months in good-grade subarachnoid hemorrhage patients with secondary deterioration?
The introduction of invasive neuromonitoring to guide delayed cerebral ischemia treatment in good-grade subarachnoid hemorrhage patients with secondary deterioration may increase the rate of good recovery and reduce infarction load.
Answers are grounded in this paper and cite their sources.
INM may guide DCI treatment when neurological assessment fails in good-grade SAH; leaves open need for prospective trials before practice change.
Background Good-grade aneurysmal subarachnoid hemorrhage (Hunt and Hess 1–2) is generally associated with a favorable prognosis. Nonetheless, patients may still experience secondary deterioration due to delayed cerebral ischemia (DCI), contributing to poor outcome. In those patients, neurological assessment is challenging and invasive neuromonitoring (INM) may help guide DCI treatment. Methods An observational analysis of 135 good-grade SAH patients referred to a single tertiary care center between 2010 and 2018 was performed. In total, 54 good-grade SAH patients with secondary deterioration evading further neurological assessment, were prospectively enrolled for this analysis. The cohort was separated into two groups: before and after introduction of INM in 2014 (pre-INM SecD : n = 28; post-INM SecD : n = 26). INM included either parenchymal oxygen saturation measurement (p ti O 2 ), cerebral microdialysis or both. Episodes of DCI (p ti O 2 < 10 mmHg or lactate/pyruvate > 40) were treated via induced hypertension or in refractory cases by endovascular means. The primary outcome was defined as the extended Glasgow outcome scale after 12 months. In addition, we recorded the amount of imaging studies performed and the occurrence of silent and overall DCI-related infarction. Results Secondary deterioration, impeding neurological assessment, occurred in 54 (40.0%) of all good-grade SAH patients. In those patients, a comparable rate of favorable outcome at 12 months was observed before and after the introduction of INM (pre-INM SecD 14 (50.0%) vs. post-INM SecD 16, (61.6%); p = 0.253). A significant increase in good recovery (pre-INM SecD 6 (50.0%) vs. post-INM SecD 14, (61.6%); p = 0.014) was observed alongside a reduction in the incidence of silent infarctions (pre-INM SecD 8 (28.6%) vs. post-INM SecD 2 (7.7%); p = 0.048) and of overall DCI-related infarction (pre-INM SecD 12 (42.8%) vs. post-INM SecD 4 (23.1%); p = 0.027). The number of CT investigations performed during the DCI time frame decreased from 9.8 ± 5.2 scans in the pre-INM SecD group to 6.1 ± 4.0 ( p = 0.003) in the post-INM SecD group. Conclusions A considerable number of patients with good-grade SAH experiences secondary deterioration rendering them neurologically not assessable. In our cohort, the introduction of INM to guide DCI treatment in patients with secondary deterioration increased the rate of good recovery after 12 months. Additionally, a significant reduction of CT scans and infarction load was recorded, which may have an underestimated impact on quality of life and more subtle neuropsychological deficits common after SAH.
No takes yet. Share an insight, caveat, or question.
Veldeman et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: